20/20 GeneSystems Inc., of Rockville, Md., named David Sidransky chair of its scientific advisory board.

Allos Therapeutics Inc., of Denver, appointed Markus Herzig vice president of regulatory affairs and Pablo Cagnoni director, clinical development.

Altas Venture, of Boston, appointed Robert Badavas principal and chief operating officer, effective Sept. 1. Separately, it added Jay Shiveley as principal in its Menlo Park, Calif., office.

Biogen Inc., of Cambridge, Mass., appointed Sylvie Grigoire executive vice president, technical operations.

Cell Genesys Inc., of Foster City, Calif., promoted Joseph Vallner to president.

DNA Sciences Inc., of Fremont, Calif., appointed Mark Perry and Kenneth Melmon to its board.

GeneProt Inc., of Evanston, Ill., appointed Bertrand Damour chief financial officer, Stephen Macevicz vice president, intellectual property, and Diana Wetmore chief technical officer for the company┬┐s Geneva, Switzerland, branch.

Genetix Group plc, of New Milton, UK, appointed Rod Wing to its scientific advisory board.

Genome Therapeutics Corp., of Waltham, Mass., elected David Stone to its board.

Hollis-Eden Pharmaceuticals Inc., of San Diego, appointed Dominick Auci scientific investigator for allergy, immunology and inflammation.

ILEX Oncology Inc., of San Antonio, named Richard Bryce director of medical affairs.

InterMune Inc., of Brisbane, Calif., appointed Steven Porter vice president of clinical research; Mack Mabry senior director of clinical research-oncology; Michael Crager senior director, biostatistics; and Williamson Bradford director of clinical research-pulmonary. It promoted Henry Hsu to vice president of clinical research.

Lexicon Genetics Inc., of The Woodlands, Texas, added David Kimball as senior director of medicinal chemistry; named Alexander Turner senior director, pharmaceutical discovery; and added Peter Cheung as senior scientist in pharmaceutical discovery.

Maxim Pharmaceuticals Inc., of San Diego, added Karl-Hermann Bremeyer as vice president, European operations; Sean Reade as executive director, global regulatory affairs; and Mark Knowles as senior director, biostatistics.

MedImmune Inc., of Gaithersburg, Md., promoted Ripley Ballou to vice president and group leader, clinical research; David Carlin to vice president and group leader, biostatistics and data management; and Robert Earhart to vice president, clinical research. Also, MedImmune added Jeffrey Hackman as vice president, marketing; Peter Kiener as vice president, research; and Peter Patriarca as vice president, regulatory affairs.

nautilus biotech, of Paris, added Abderrahim Mahfoudi as director of corporate development.

NeoTherapeutics Inc., of Irvine, Calif., added Rosemarie Rosales as assistant director, medical research of NeoOncoRx.

Nymox Pharmaceutical Corp., of Maywood, N.J., appointed Paul Kraus clinical consultant.

RxKinetix Inc., of Louisville, Colo., named Janice Troha vice president of clinical development and regulatory affairs.

Telik Inc., of South San Francisco, appointed Jacqueline Dombroski vice president, regulatory affairs and quality assurance.

Therion Biologics Corp., of Cambridge, Mass., appointed Jeff Edelson chief medical officer and senior vice president of clinical development and Michael Wyand senior vice president of research and development.

Trimeris Inc., of Durham, N.C., elected Kevin Tang to its board.

No Comments